Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development

Frontiers in Immunology

Volumn 3, Issue AUG, 2012, Pages

  Ancans, Janis ^a  

^a UNIVERSITY OF LATVIA   (Latvia)

Author keywords

Advanced therapy medicinal product; Cell therapy medicinal product; Committee foradvancedtherapies; Hospital exemption; Mesenchymal stem progenitor cell; National competent authority

Indexed keywords

EID: 84874217844     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00253     Document Type: Review

References (12)

1. Buchholz, C. J., Sanzenbacher, R., and Schüle, S. (2012). The European hospital exemption clause - new option for gene therapy? Hum. Gene Ther. 23, 7-12.
2. Committee for Advanced Therapies (CAT), and CAT Scientific Secretariat. (2010). Challenges with advanced therapy medicinal products and how to meet them. Nat. Rev. Drug Discov. 9, 195-201.
3. Eichler, H. G., Oye, K., Baird, L. G., Abadie, E., Brown, J., Drum, C. L., Ferguson, J., Garner, S., Honig, P., Hukkelhoven, M., Lim, J. C., Lim, R., Lumpkin, M. M., Neil, G., O'Rourke, B., Pezalla, E., Shoda, D., Seyfert-Margolis, V., Sigal, E. V., Sobotka, J., Tan, D., Unger, T. F., and Hirsch, G. (2012). Adaptive licensing: taking the next step in the evolution of drug approval. Clin. Pharmacol. Ther. 91, 426-437.
4. Li, T. S., Cheng, K., Malliaras, K., Smith, R. R., Zhang, Y., Sun, B., Matsushita, N., Blusztajn, A., Terrovitis, J., Kusuoka, H., Marbán, L., and Mar-bán, E. (2012). Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J. Am. Coll. Cardiol. 59, 942-953.
5. Mahalatchimy, A., Rial-Sebbag, E., Tournay, V., and Faulkner, A. (2012). The legal landscape for advanced therapies: material and institutional implementation of European Union Rules in France and the United Kingdom. J. Law Soc. 39, 131-149.
6. Olson, S. D., Pollock, K., Kambal, A., Cary, W., Mitchell, G. M., Tempkin, J., Stewart, H., McGee, J., Bauer, G., Kim, H. S., Tempkin, T., Wheelock, V., Annett, G., Dunbar, G., and Nolta, J. A. (2012) Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease. Mol. Neurobiol. 45, 87-98.
7. Prockop, D. J., and Oh, J. Y. (2012). Medical therapies with adult stem/progenitor cells (MSCs): a backward journey from dramatic results in vivo to the cellular and molecular explanations. J. Cell. Biochem. 113, 1460-1469.
8. Ranganath, S. H., Levy, O., Inamdar, M. S., and Karp, J. M. (2012) Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 10, 244-258.
9. Regnstrom, J., Koenig, F., Aronsson, B., Reimer, T., Svendsen, K., Tsigkos, S., Flamion, B., Eichler, H. G., and Vam-vakas, S. (2010). Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. Eur. J. Clin. Pharmacol. 66, 39-48.
10. Wang, S., Qu, X., and Zhao, R. C. (2012) Clinical applications of mesenchymal stem cells. J. Hematol. Oncol. 5, 19.
11. Webster, A., Haddad, C., and Waldby, C. (2011). Experimental heterogeneity and standardisation: stem cell products and the clinical trial process. Biosocieties 6, 401-419.
12. Wohn, D. Y. (2012). Korea okays stem cell therapies despite limited peer-reviewed data. Nat. Med. 18, 329.